Relations between serum magnesium and metabolic syndrome and metabolic syndrome indicators in women with endometrial carcinoma.

Abstract

Objective: To investigate the relationship between serum magnesium and metabolic syndrome (MetS) and serum metabolic parameters in endometrial cancer (EC) patients.Patients and methods: A retrospective study was designed to collect medical records of 291 patients diagnosed with EC from July 2016 to May 2021. Independent samples t-test, ANOVA, and chi-square test were used to compare whether the clinical characteristics of EC patients were statistically different across groups. Correlation analysis and partial correlation analysis were performed to determine whether there was a relationship between serum magnesium and the incidence of MetS and its components in EC patients.Results: Serum magnesium concentration was lower in postmenopausal patients (0.94±0.08 vs. 0.91±0.07; p=0.018) or patients with diabetes mellitus (DM) (0.90±0.09 vs. 0.93±0.07; p=0.005). EC patients with hypomagnesemia had a higher BMI (25.10±4.31 vs. 24.41±3.93 vs. 24.33±3.12; p=0.014) and a higher prevalence of DM (55.6% vs. 22.5% vs. 20.7%; p=0.006) and higher TG (2.29±2.95 vs 1.62±0.91 vs 1.47±0.60; p=0.046) than the other groups. The correlation between the number of MetS criteria patients met and serum magnesium concentration was calculated and there is negative correlation between them (r=-0.201; p<0.001). Significant negative correlations were also found between total serum magnesium and TG (r=-0.147; p=0.025), large waist circumference (LWC) (r=-0.133; p=0.023) and the incidence of MetS in EC patients (r=-0.101; p=0.013) after adjusting for multiple variables.Conclusions: In patients with EC, during the period of treatment, supplementation with magnesium may improve the prognosis outcome. Serum magnesium may also be a novel parameter when investigating the effect of MetS on EC.